<DOC>
	<DOC>NCT02855177</DOC>
	<brief_summary>PF-06427878 is a new compound proposed for the treatment of hyperlipidemia. The primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics after 2 weeks of dosing of PF-06427878 in overweight-obese, otherwise healthy adult subjects.</brief_summary>
	<brief_title>A Multiple Dose Safety And Pharmacokinetic (PK) Study Of PF-06427878 In Overweight-Obese, Otherwise Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Overweight</mesh_term>
	<criteria>Healthy male and/or female subjects of non childbearing potential. Body Mass Index (BMI) of &gt;=25 kg/m2; and a total body weight &gt;50 kg Subjects with liver fat &gt;=6% and &lt;=20% Evidence or history of clinically significant hematological, renal, endocrine, pulmonary,gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Hyperlipidemia</keyword>
</DOC>